相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacokinetics of exogenous GIP(1-42) in C57Bl/6 mice; Extremely rapid degradation but marked variation between available assays
Geke Aline Boer et al.
PEPTIDES (2021)
Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies for the Treatment of Obesity, Do Agonists = Antagonists?
Elizabeth A. Killion et al.
ENDOCRINE REVIEWS (2020)
The glucose-dependent insulinotropic polypeptide signaling axis in the central nervous system
A. E. Adriaenssens et al.
PEPTIDES (2020)
GIP and the gut-bone axis - Physiological, pathophysiological and potential therapeutic implications
Signe Stensen et al.
PEPTIDES (2020)
GIP analogues and the treatment of obesity-diabetes
Clifford J. Bailey
PEPTIDES (2020)
The role of GIP in α-cells and glucagon secretion
Kimberley El et al.
PEPTIDES (2020)
Molecular interactions of full-length and truncated GIP peptides with the GIP receptor - A comprehensive review
Maria Buur Nordskov Gabe et al.
PEPTIDES (2020)
Incretin therapy for diabetes mellitus type 2
Jens Juul Holst
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2020)
Full-length human GLP-1 receptor structure without orthosteric ligands
Fan Wu et al.
NATURE COMMUNICATIONS (2020)
GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
Jose Luis Gorriz et al.
JOURNAL OF CLINICAL MEDICINE (2020)
GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
Daiji Kawanami et al.
FRONTIERS IN PHARMACOLOGY (2020)
A review of GLP-1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once-weekly agents
Susan Cornell
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2020)
Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism
Elizabeth A. Killion et al.
NATURE COMMUNICATIONS (2020)
Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes
Natasha Chidekel Bergmann et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
GIP and GLP-1: Stepsiblings Rather Than Monozygotic Twins Within the Incretin Family
Michael A. Nauck et al.
DIABETES (2019)
Reductions in Insulin Resistance are Mediated Primarily via Weight Loss in Subjects With Type 2 Diabetes on Semaglutide
Vivian A. Fonseca et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Free fatty acid receptors, G protein-coupled receptor 120 and G protein-coupled receptor 40, are essential for oil-induced gastric inhibitory polypeptide secretion
Akiko Sankoda et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
Understanding the mechanisms of reversal of type 2 diabetes
Roy Taylor et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Paracrine crosstalk between intestinal L- and D-cells controls secretion of glucagon-like peptide-1 in mice
Sara L. Jepsen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2019)
Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake
Alice E. Adriaenssens et al.
CELL METABOLISM (2019)
Glucagon-like peptide 1 (GLP-1)
T. D. Mueller et al.
MOLECULAR METABOLISM (2019)
Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity
Habib Yaribeygi et al.
LIFE SCIENCES (2019)
Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals
Laerke S. Gasbjerg et al.
DIABETES (2019)
Preproglucagon Neurons in the Nucleus of the Solitary Tract Are the Main Source of Brain GLP-1, Mediate Stress-Induced Hypophagia, and Limit Unusually Large Intakes of Food
Marie K. Holt et al.
DIABETES (2019)
Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
Michael A. Nauck et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2019)
Bile acids drive colonic secretion of glucagon-like-peptide 1 and peptide-YY in rodents
Charlotte Bayer Christiansen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2019)
Peptone-mediated glucagon-like peptide-1 secretion depends on intestinal absorption and activation of basolaterally located Calcium-Sensing Receptors
Ida M. Modvig et al.
PHYSIOLOGICAL REPORTS (2019)
Physiology of the Incretin Hormones, GIP and GLP-1-Regulation of Release and Posttranslational Modifications
Jens J. Holst et al.
COMPREHENSIVE PHYSIOLOGY (2019)
Human GIP(3-30)NH2 inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not rodent GIP receptors
Maria Buur Nordskov Gabe et al.
BIOCHEMICAL PHARMACOLOGY (2018)
A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trials
Carolyn F. Deacon
DIABETES OBESITY & METABOLISM (2018)
Calcium-sensing receptor-mediated L-tryptophan-induced secretion of cholecystokinin and glucose-dependent insulinotropic peptide in swine duodenum
Xiuying Zhao et al.
JOURNAL OF VETERINARY SCIENCE (2018)
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
Richard E. Pratley et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Bile acids are important direct and indirect regulators of the secretion of appetite- and metabolism-regulating hormones from the gut and pancreas
Rune E. Kuhre et al.
MOLECULAR METABOLISM (2018)
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies et al.
DIABETES CARE (2018)
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Juan Pablo Frias et al.
LANCET (2018)
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models
Elizabeth A. Killion et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Tamer Coskun et al.
MOLECULAR METABOLISM (2018)
GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study
Laerke S. Gasbjerg et al.
DIABETOLOGIA (2018)
A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents
Pia K. Norregaard et al.
DIABETES OBESITY & METABOLISM (2018)
Enteroendocrine K and L cells in healthy and type 2 diabetic individuals
Tina Jorsal et al.
DIABETOLOGIA (2018)
Diabetes mellitus, a state of low bone turnover - a systematic review and meta-analysis
Katrine Hygum et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2017)
GHRELIN, CCK, GLP-1, AND PYY(3-36): SECRETORY CONTROLS AND PHYSIOLOGICAL ROLES IN EATING AND GLYCEMIA IN HEALTH, OBESITY, AND AFTER RYGB
Robert E. Steinert et al.
PHYSIOLOGICAL REVIEWS (2017)
The acute glucose lowering effect of specific GPR120 activation in mice is mainly driven by glucagon-like peptide 1
Linda Sundstrom et al.
PLOS ONE (2017)
Chylomicrons stimulate incretin secretion in mouse and human cells
Arianna Psichas et al.
DIABETOLOGIA (2017)
The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor
Meena Asmar et al.
DIABETES (2017)
Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response
Sravan K. Thondam et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2017)
Glucagon and Amino Acids Are Linked in a Mutual Feedback Cycle: The Liver-α-Cell Axis
Jens J. Holst et al.
DIABETES (2017)
Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors
A. H. Sparre-Ulrich et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes
Michael A. Nauck et al.
DIABETES CARE (2016)
Cephalic phase secretion of insulin and other enteropancreatic hormones in humans
Simon Veedfald et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2016)
Internalized Receptor for Glucose-dependent Insulinotropic Peptide stimulates adenylyl cyclase on early endosomes
Sadek Ismail et al.
BIOCHEMICAL PHARMACOLOGY (2016)
The Extracellular Surface of the GLP-1 Receptor Is a Molecular Trigger for Biased Agonism
Denise Wootten et al.
CELL (2016)
Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes
A. Mari et al.
DIABETES OBESITY & METABOLISM (2016)
GPR119, a Major Enteroendocrine Sensor of Dietary Triglyceride Metabolites Coacting in Synergy With FFA1 (GPR40)
Jeppe H. Ekberg et al.
ENDOCRINOLOGY (2016)
Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption
Jennifer S. ten Kulve et al.
JOURNAL OF ENDOCRINOLOGY (2016)
Mechanisms underlying glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 secretion
Frank Reimann et al.
JOURNAL OF DIABETES INVESTIGATION (2016)
Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men
Ali Asmar et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2015)
Gut chemosensing mechanisms
Arianna Psichas et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Liraglutide, a Glucagon-Like Peptide-1 Analog, Increased Insulin Sensitivity Assessed by Hyperinsulinemic-Euglycemic Clamp Examination in Patients with Uncontrolled Type 2 Diabetes Mellitus
Hideaki Jinnouchi et al.
JOURNAL OF DIABETES RESEARCH (2015)
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Brian Finan et al.
NATURE MEDICINE (2015)
Glucagon-Like Peptide 1 Recruits Muscle Microvasculature and Improves Insulin's Metabolic Action in the Presence of Insulin Resistance
Weidong Chai et al.
DIABETES (2014)
The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus
Mikkel Christensen et al.
EXPERT OPINION ON DRUG DISCOVERY (2014)
Glucose-dependent Insulinotropic Polypeptide: Blood Glucose Stabilizing Effects in Patients With Type 2 Diabetes
Mikkel B. Christensen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
A Functional Amino Acid Substitution in the Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) Gene Is Associated With Lower Bone Mineral Density and Increased Fracture Risk
S. S. Torekov et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
A Naturally Occurring GIP Receptor Variant Undergoes Enhanced Agonist-Induced Desensitization, Which Impairs GIP Control of Adipose Insulin Sensitivity
Sameer Mohammad et al.
MOLECULAR AND CELLULAR BIOLOGY (2014)
The Role of SGLT1 and GLUT2 in Intestinal Glucose Transport and Sensing
Pia V. Roeder et al.
PLOS ONE (2014)
Hindbrain GLP-1 receptor-mediated suppression of food intake requires a PI3K-dependent decrease in phosphorylation of membrane-bound Akt
Laura E. Rupprecht et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2013)
The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty
Astrid Plamboeck et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2013)
Calcium-sensing receptor (CaSR): Pharmacological properties and signaling pathways
Arthur D. Conigrave et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Oligopeptides stimulate glucagon-like peptide-1 secretion in mice through proton-coupled uptake and the calcium-sensing receptor
Eleftheria Diakogiannaki et al.
DIABETOLOGIA (2013)
Incretin hormones and the satiation signal
J. J. Holst
INTERNATIONAL JOURNAL OF OBESITY (2013)
A Novel Glucagon-like Peptide-1 (GLP-1)/Glucagon Hybrid Peptide with Triple-acting Agonist Activity at Glucose-dependent Insulinotropic Polypeptide, GLP-1 and Glucagon Receptors and Therapeutic Potential in High Fat-fed Mice
Victor A. Gault et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Brian Finan et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Predominant role of active versus facilitative glucose transport for glucagon-like peptide-1 secretion
H. E. Parker et al.
DIABETOLOGIA (2012)
Regulation of Adipocyte Formation by GLP-1/GLP-1R Signaling
Tenagne Delessa Challa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
The regulation of K- and L-cell activity by GLUT2 and the calcium-sensing receptor CasR in rat small intestine
Oliver J. Mace et al.
JOURNAL OF PHYSIOLOGY-LONDON (2012)
Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs
K. R. Hjollund et al.
DIABETOLOGIA (2011)
Glutamine Triggers and Potentiates Glucagon-Like Peptide-1 Secretion by Raising Cytosolic Ca2+ and cAMP
Gwen Tolhurst et al.
ENDOCRINOLOGY (2011)
2-Oleoyl Glycerol Is a GPR119 Agonist and Signals GLP-1 Release in Humans
Katrine B. Hansen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Differential processing of pro-glucose-dependent insulinotropic polypeptide in gut
Yukihiro Fujita et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2010)
Leptin Directly Depolarizes Preproglucagon Neurons in the Nucleus Tractus Solitarius Electrical Properties of Glucagon-Like Peptide 1 Neurons
Kazunari Hisadome et al.
DIABETES (2010)
Glucose-Dependent Insulinotropic Polypeptide May Enhance Fatty Acid Re-esterification in Subcutaneous Abdominal Adipose Tissue in Lean Humans
Meena Asmar et al.
DIABETES (2010)
Glucose-Dependent Insulinotropic Polypeptide Is Expressed in Pancreatic Islet α-Cells and Promotes Insulin Secretion
Yukihiro Fujita et al.
GASTROENTEROLOGY (2010)
GIP and GLP-1, the two incretin hormones: Similarities and differences
Yutaka Seino et al.
JOURNAL OF DIABETES INVESTIGATION (2010)
Role of MGAT2 and DGAT1 in the release of gut peptides after triglyceride ingestion
Mayumi Okawa et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes
P. V. Hojberg et al.
DIABETOLOGIA (2009)
Evidence that Intestinal Glucagon-Like Peptide-1 Plays a Physiological Role in Satiety
Diana L. Williams et al.
ENDOCRINOLOGY (2009)
Suppression of p38 MAPK and JNK via Akt-mediated Inhibition of Apoptosis Signal-regulating Kinase 1 Constitutes a Core Component of the β-Cell Pro-survival Effects of Glucose-dependent Insulinotropic Polypeptide
Scott B. Widenmaier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes
Victor A. Gault et al.
BIOCHEMICAL PHARMACOLOGY (2008)
Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion
Sara Edfalk et al.
DIABETES (2008)
Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake
Darleen A. Sandoval et al.
DIABETES (2008)
Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas
J. de Heer et al.
DIABETOLOGIA (2008)
Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass
Carel W. le Roux et al.
ANNALS OF SURGERY (2007)
Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats
Torsten P. Vahl et al.
ENDOCRINOLOGY (2007)
Biology of incretins: GLP-1 and GIP
Laurie L. Baggio et al.
GASTROENTEROLOGY (2007)
Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects
Birgitte Sloth et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2007)
Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes - A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascade
Su-Jin Kim et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Glucagon-like peptide 1 secretion by the L-cell - The view from within
Gareth E. Lim et al.
DIABETES (2006)
Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: Relationships with postprandial glycemic and insulinemic responses
TJ Little et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Prohormone convertase 1/3 is essential for processing of the glucose-dependent insulinotropic polypeptide precursor
R Ugleholdt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
GIP(Lys16PAL) and GIP(LyS37PAL):: Novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential
N Irwin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig
A Plamboeck et al.
DIABETOLOGIA (2005)
The inhibitory effects of peripheral administration of peptide YY3-36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway
CR Abbott et al.
BRAIN RESEARCH (2005)
Mechanisms of peptide and nonpeptide ligand binding to class B G-protein coupled receptors
SRJ Hoare
DRUG DISCOVERY TODAY (2005)
Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus
OG Kolterman et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2005)
Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells
A Nakagawa et al.
AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL (2004)
Neural regulation of glucagon-like peptide-1 secretion in pigs
L Hansen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2004)
Gastric distension induces c-Fos in medullary GLP-1/2-containing neurons
N Vrang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2003)
Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus
T Vilsboll et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia
JJ Meier et al.
DIABETOLOGIA (2003)
A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line
FM Gribble et al.
DIABETES (2003)
Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats
L Farilla et al.
ENDOCRINOLOGY (2002)
Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients
T Vilsboll et al.
DIABETOLOGIA (2002)
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
K Miyawaki et al.
NATURE MEDICINE (2002)
GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion
CF Deacon et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2002)
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes:: a parallel-group study
M Zander et al.
LANCET (2002)
Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats
SA Hinke et al.
DIABETES (2002)
Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers
CMB Edwards et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2001)
Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs
CF Deacon et al.
DIABETES (2001)
Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration
LB Knudsen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
分享论文
